
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1552219
This article is part of the Research Topic Novel Strategies for the Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome View all 4 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
AbstractBackground: The precise function of the hs-CRP/HDL-C ratio in forecasting the long-term mortality risk of patients with stages 1-4 of Cardiovascular-Kidney-Metabolic (CKM) syndrome remains inadequately delineated. This study investigates the potential correlation between the hs-CRP/HDL-C ratio and long-term mortality risk in individuals with CKM syndrome stages 1-4..Methods: This prospective cohort study utilises data from the China Health and Retirement Longitudinal Study (CHARLS) project, encompassing 6,719 people who satisfied stringent criteria. We developed three Cox proportional hazards regression models to investigate the potential relationship between the hs-CRP/HDL-C ratio and long-term mortality risk in patients with CKM stages 1-4. We employed Restricted Cubic Spline (RCS) curves for analysis to identify any potential nonlinear correlations. Furthermore, we performed Receiver Operating Characteristic (ROC) curve analysis to evaluate predictive performance and identify the appropriate cut-off value. To enhance the research findings, we conducted a stratified analysis to investigate the influence of various sociodemographic factors on this association.Results: In individuals with CKM syndrome stages 1-4, the 10-year incidence of all-cause mortality was 14.1%. Upon controlling for additional potential confounding variables, the outcomes of the Cox proportional hazards regression model distinctly demonstrated a statistically significant linear positive association between the hs-CRP/HDL-C ratio and the long-term mortality risk in patients. For each quartile increase in the hs-CRP/HDL-C ratio, the probability of poor outcomes (i.e., mortality) escalated by 15% (Hazard Ratio, HR = 1.15, 95% Confidence Interval, CI: 1.09–1.22, p-value < 0.001). Moreover, the integration of the hs-CRP/HDL-C ratio into the baseline risk prediction model, with all pertinent factors thoroughly adjusted, markedly enhanced the model's predictive capacity, facilitating a more precise assessment of long-term mortality risk in patients with CKM syndrome stages 1-4.Conclusion: This study identified a positive linear association between the hs-CRP/HDL-C ratio and long-term mortality risk in patients with stages 1 to 4 of CKM syndrome. This remarkable discovery not only offers a crucial reference for enhancing early individualised treatment options but also greatly aids in the early identification of patients with poor prognoses, hence presenting a novel perspective for improving clinical management pathways for these individuals.
Keywords: cardiovascular-kidney-metabolic syndrome, High-sensitivity C-reactive protein, High-density lipoprotein cholesterol, Mortality, CHARLS
Received: 27 Dec 2024; Accepted: 21 Mar 2025.
Copyright: © 2025 han, guo, zhang and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yang Zheng, First Affiliated Hospital of Jilin University, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.